Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:moclobemide
|
| gptkbp:ATCCode |
N06AG02
|
| gptkbp:CASNumber |
71320-77-9
|
| gptkbp:chemicalFormula |
C13H17NO2
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:contraindication |
gptkb:pheochromocytoma
severe liver impairment |
| gptkbp:drugClass |
reversible inhibitor of monoamine oxidase A
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Manerix
|
| gptkbp:interactsWith |
gptkb:tricyclic_antidepressants
gptkb:SSRIs gptkb:meperidine |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Lundbeck
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache insomnia dry mouth |
| gptkbp:status |
approved in Canada
approved in Europe |
| gptkbp:usedFor |
gptkb:depression
|
| gptkbp:bfsParent |
gptkb:Moclobemide
|
| gptkbp:bfsLayer |
7
|